Skip to main content
Yingchang Mi on Muck Rack

Yingchang Mi

As seen in: Nature, Wiley Online Library, Diagnostic Pathology, Journal of Infection
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yingchang

Contact Yingchang, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Venetoclax combined with intensive chemotherapy as induction chemotherapy in newly diagnosed AML with FLT3-ITD-mutation

|
By Yuyu Liu, Xingli Zhao, Xiaohui Suo, Yanliang Bai, Fang Zheng, Weihua Zhao, Hongling Peng, Dongmei Wang, Liyun Zhao, Jie Liu, Zeping Zhou, Yingchang Mi, Kaiqi Liu, Guanchen Bai
| Nature Verified
Dear Editor The FMS-internal tandem duplication (FLT3-ITD) is found in approximately 20–25% of de novo AML. Improvements in overall survival (OS) have been achieved with the development of FLT3 inhibitors (midostaurin, quizartinib, and gilteritinib) and allogeneic hematopoietic stem-cell transplantation (allo-HSCT) [1,2,3]. Consequently, the 2022 European Leukemia Network (ELN) guidelines reclassified FLT3-ITD-mutated AML as intermediate risk disease.
Open in Who Shared Issue with article?

Gene- and subtype-dependent prognostic impact of ras pathway mutations in acute myeloid leukemia: a cohort study of 2,500 patients

|
By Heng Shen, Yan Hui, Yuntao Liu, Dong Lin, Qiuyun Fang, Ying Wang, Benfa Gong, Chunlin Zhou, Kaiqi Liu, Guangji Zhang, Xiaoyuan Gong, Shaowei Qiu, Bingcheng Liu, Yingchang Mi, Jianxiang Wang, Hui Wei, Shouyun Li
| Nature Verified
To the Editor: Acute myeloid leukemia (AML) is a hematologic malignancy driven by diverse molecular aberrations [1, 2]. Constitutive activation of signal transduction pathways is a hallmark of leukemogenesis [1, 3]. Among these, the RAS/MAPK signaling pathway is a central regulator of critical cellular processes, including proliferation, differentiation, and apoptosis [4].
Open in Who Shared Issue with article?

CBFB::MYH11 MRD after the second chemotherapy cycle: a guide for allogeneic transplantation in favorable-risk AML

|
By Mingyang Wang, Guangji Zhang, Wenwen guo, Haixiao Zhang, Jiaxin Cao, Jieya Luo, Miao Yang, Yigeng Cao, Fengjiao Wang, Rongli Zhang, Xin McRae Chen, Weihua Zhai, Qiaoling Ma, Jialin Wei, Donglin Yang, Yi He, Sizhou Feng, Mingzhe Han, Yingchang Mi, Jianxiang Wang, Hui Wei, Erlie Jiang
| Nature Verified
Abstract Although acute myeloid leukemia (AML) with CBFB::MYH11 rearrangement is classified as favorable-risk, approximately 40% of patients experience relapse. We evaluated the prognostic impact of CBFB::MYH11 transcript levels and the optimal timing of allogeneic hematopoietic cell transplantation (allo-HCT) at first complete remission (CR1). A total of 186 patients with CBFB::MYH11-rearranged AML treated with intensive induction chemotherapy were included.
Open in Who Shared Issue with article?
See all 7 articles